I think that the combination of Resverlogix and Zenith would make sense with right equity issue and uplisting to the Nasdaq. Let's get some large banking institutions behind the story and let them sell it to investors south of the border. As mentioned, the combined entity would have multiple ongoing trials and would therefore reduce the risk to shareholders of one trial failure. Given the scaffold and its numerous chemical entities, risk should be reduced anyway. Furthermore, by removing any royalty issues and by ensuring credit line issues are dealt with, the name would be much cleaner for investors to buy. Evidently, there would be many factors involved in making this happen. For instance, what valuation would be placed on Zenith shares? $1 US? Depending on where the valuation is placed, many Zenith holders may not vote for the combination. Although they would suddenly have liquidity, they may not be satisfied with a "grey" market valuation. Bfw